Drug Discovery
Innovation Programme

Since 2002, Affygility Solutions has provided occupational toxicology, industrial hygiene, and occupational health and safety services to the biotechnology, pharmaceutical, and medical device industries. Trusted by more than 800 clients across 75+ countries, Affygility helps organizations simplify complex compliance processes, protect worker safety, and accelerate product development timelines. Its services include Occupational Exposure Limits (OELs), Acceptable Daily Exposure (ADE) values, Occupational Health Categorization (OHC) reports, Safety Data Sheets (SDSs), and custom toxicology monographs for proprietary compounds. Through its OEL Fastrac+ platform, Affygility delivers fast, accurate toxicology data to support cleaning validation, manufacturing, and regulatory compliance decisions. With an international team based in the United States, Canada, Brazil, Singapore, and the United Arab Emirates, Affygility combines deep scientific expertise with innovative technology to support life sciences organizations worldwide.

Maxwell Biosciences has developed technology that can mimic 10,000+ peptides that naturally exist in the human body, a biomimetic immune system. Our vision is to create health for the world, safely and affordably. Our peptide mimics (Claromers®) have the ability to destroy pathogenic viruses, fungi, bacteria and biofilms without harming healthy cells. Claromers are shelf-stable, microbiome-resilient and low cost. Originally developed for critical infectious diseases, Maxwell’s technology is now entering non-pharmaceutical commercial deployment across cosmetics, personal care, medical coatings and biodefense—with pilot access for select partners. Backed by a decade of research, a robust patent portfolio and leadership with deep expertise in science, military, AI and global health, Maxwell has active collaborative agreements with the US military and governments worldwide. FDA clinical trials are planned for 2026. Maxwell’s AI-first platform enables rapid innovation against the rising threat of resistant pathogens, offering scalable solutions for a healthier planet.

CN1699 is a global medical media platform connecting academia, healthcare institutions, and industry professionals through multilingual news, academic content, and digital outreach. With active networks in Asia, Central Asia & the Caucasus, the Middle East, Europe, and Africa, it supports over 500,000 healthcare users. Key services include the MDLA Digital Library, offering academic resources to universities and libraries, and WeMed, a collaboration program linking medical schools, events, and experts worldwide. As an official media partner for international healthcare exhibitions, CN1699 provides bilingual promotional support through its websites, newsletters, and social media, helping events and organizations achieve targeted visibility and academic impact across global medical markets.

Biocytogen is a global biotech company that drives the discovery of fully human monoclonal, bispecific, multispecific, ADC, VHH, and TCR-mimic antibodies across 1,000+ druggable targets, providing 1M+ authentic antibody sequences through its RenBiologicsTM sub-brand for partnerships. Biocytogen is advancing antibody drug development through innovative technologies. Leveraging gene-editing expertise, it pioneered drug target knock-in humanized models and offers 4,000+ models via BioMiceTM, along with in vivo, ex vivo, and in vitro pharmacology and custom gene-editing services.

Sai Life Sciences is an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO) that works with over 300 global innovator pharma and biotech companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes. Over the past 26 years, Sai Life Sciences has served a diverse set of programmes, consistently delivering value based on its quality and responsiveness. The company has over 3,400 employees across its facilities in India, UK, USA and Japan.

IRBM is a scientific contract research organization (CRO) that stands at the forefront of drug discovery, leveraging a single, unified research facility to accelerate team-based breakthroughs and improve efficiencies from concept to candidate. With a history of contributing to several approved drugs, and its own internal pipeline of oncology and other therapeutic assets, IRBM is powered by deep collaborations and decades of expertise from leading global institutions. Their comprehensive in-house capabilities assist partners in achieving key milestones and progressing towards clinical readiness, positioning IRBM as a major player in driving innovation in the pharmaceutical and biotech fields.